Astellas Pharma (OTCMKTS:ALPMY) Posts Quarterly Earnings Results

Astellas Pharma (OTCMKTS:ALPMY) issued its quarterly earnings data on Wednesday. The company reported $0.13 earnings per share (EPS) for the quarter, reports. The business had revenue of $3.11 billion during the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%.

Astellas Pharma Price Performance

Shares of OTCMKTS ALPMY opened at $11.66 on Friday. The firm’s 50-day simple moving average is $11.94 and its 200 day simple moving average is $10.84. The stock has a market cap of $21.10 billion, a P/E ratio of 55.53 and a beta of 0.37. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26. Astellas Pharma has a fifty-two week low of $9.15 and a fifty-two week high of $13.14.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.